Clinical trials: Human Immunodeficiency Virus Type 1
HIV Infections, Men
Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging
This study will evaluate the impact of U=U messaging and counseling on gaps in the HIV care cascade for men, including testing uptake and ART initiation (Aim 1), achieving viral suppression and retention in care (Aim 2) in two…
- Conditions
- HIV Infections, Men, Treatment Adherence
- Trial name
- NCT05602376
- Testing
- U=U testing messaging scripts, U=U adherence messaging scripts
- Where
- 2 sites in South Africa
- Volunteers
- 3,642 people, healthy volunteers welcome
- Sponsor
- Desmond Tutu HIV Foundation
HIV Infections
Immunologic Control of Drug Resistant HIV
Drug resistant HIV strains often develop in patients who have taken anti-HIV drugs for an extended time. However, these drug resistant HIV strains do not always cause an increase in the level of HIV in the blood.
- Trial name
- NCT00053404
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection
Effect of Dolutegravir Intensification on HIV-1 Reservoirs
Persistent HIV viremia occurs in most ART-treated patients and could arise from reactivation of viral expression from latently-infected cells that constitute the viral latent reservoir (LR) and/or residual ongoing viral…
- Trial name
- EDIT (NCT05351684)
- Testing
- Dolutegravir 50 MG
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University of Liege
HIV
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an…
- Trial name
- SUPPRESS (NCT01605084)
- Testing
- Atazanavir, Darunavir, Ritonavir
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Volunteers to Evaluate Accelerated Vaccine Schedules
To evaluate the safety and immunogenicity of an accelerated schedule of recombinant canarypox vaccine ALVAC-HIV MN120TMG (vCP205) versus control followed by boost with rgp120/HIV-1 SF2 vaccine in HIV-negative volunteers.
- Trial name
- NCT00001076
- Testing
- ALVAC-HIV MN120TMG (vCP205), ALVAC-RG Rabies Glycoprotein (vCP65), rgp120/HIV-1 SF-2
- Where
- 3 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV -1 Infection
Study of GS-0415 and How It Works in People With HIV
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and…
- Trial name
- NCT07719491
- Testing
- GS-0415
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Gilead Sciences
HIV-1 Infection
Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of boosted…
- Trial name
- NCT02603107
- Testing
- RTV, ATV, DRV
- Where
- 119 sites in United States, Australia and 9 more
- Volunteers
- 578 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus (HIV)
ComBaCaL HIV Prevention TwiCs
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for…
- Trial name
- CoPrev (NCT07581600)
- Testing
- CoPrev model, Referral to the nearest responsible health facility
- Where
- 2 sites in Lesotho, Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
HIV
PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color
This is a 48-week prospective observational study that will allow testing of the hypothesis that a program in which pre-exposure prophylaxis (PrEP) is administered to young men of color who have sex with men (yMSMc) in a…
- Trial name
- NCT02367807
- Testing
- Emtricitabine and tenofovir disoproxil fumarate
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Philadelphia Fight
Human Immunodeficiency Virus
An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children
The primary purpose of this study is to determine the pharmacokinetic properties (what the body does to maraviroc) and to determine a suitable dosing schedule of maraviroc in HIV-1 infected children and adolescents.
- Trial name
- NCT00791700
- Testing
- Maraviroc
- Where
- 41 sites in United States, Brazil and 7 more
- Volunteers
- 103 people
- Sponsor
- ViiV Healthcare
PrEP, PrEP Adherence Monitoring
Prevention ICONA Dedicated Ensemble
Despite significant advances in HIV treatment, transmission remains a public health concern. In 2022, there were 1.3 million new HIV infections worldwide and 1,888 new diagnoses in Italy, with sexual transmission being the…
- Conditions
- PrEP, PrEP Adherence Monitoring, HIV, HIV -1 Infection
- Trial name
- PrIDE (NCT07186244)
- Where
- 53 sites in Italy
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fondazione ICONA
HIV Infection
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
This is a 48-week study to collect additional information on the safety, tolerability, pharmacokinetics, and antiviral activity of an investigational regimen (course of therapy) including FDA approved HIV drugs in HIV-infected…
- Trial name
- NCT00040664
- Testing
- ritonavir, fosamprenavir
- Where
- 42 sites in United States, Canada and 5 more
- Volunteers
- 69 people
- Sponsor
- ViiV Healthcare
Herpes Genitalis, HIV Infection
Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding
Genital herpes is a long-life sexually transmitted diseases which infects a large proportion of women in Africa. Its clinical symptoms are painful sores on the genitals, which heals after a few days.
- Trial name
- NCT00158509
- Testing
- Valacyclovir
- Where
- Burkina Faso
- Volunteers
- 215 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Patients
Beta-2 Microglobulin and Serum Cytokines x HAART
Cross-sectional study to assess the behavior of Beta-2 microglobulin and serum cytokines TNF-α, IFN-γ, IL-2, IL-4 and IL-10 as indicators of highly active antiretroviral therapy (HAART) failure.
- Trial name
- NCT00831207
- Where
- Brazil
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
HIV-1-infection
Testing the Safety and Efficacy of Commercial Drug Biktarvy in Subjects Known to Have the 184 Resistance Mutation to a Component in Biktarvy
An Open-Label Study to Evaluate Switching from a Regimen of Elvitegravir/Tenofovir alafenamide/Emtricitabine/Cobicistat and Darunavir, to a Fixed-Dose Combination of Bictegravir/Tenofovir alafenamide/Emtricitabine in…
- Trial name
- NCT04040075
- Testing
- Biktarvy Tab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Southampton Healthcare, Inc.
HIV-1-infection
The Effect of Biktarvy (B/F/TAF) on Whole-body Insulin Sensitivity, Lipid and Endocrine Profile in Healthy Volunteers
This study will investigate changes in insulin sensitivity, lipid metabolism and endocrine profile in HIV-negative subjects exposed to Biktarvy (B/F/TAF) compared to subject not exposed to B/F/TAF for 28 days.
- Trial name
- NCT04950530
- Testing
- BIKTARVY 50Mg-200Mg-25Mg Tablet
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
HIV Infections
A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3
PRIMARY: To compare the immunogenicity and safety of each of several HIV-1 derived immunogens versus control in HIV-infected individuals with CD4 counts greater than or equal to 500 cells/mm3.
- Trial name
- NCT00000779
- Testing
- Aluminum hydroxide, MF59, rgp120/HIV-1IIIB
- Where
- 10 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
For patients who are starting to take antiretroviral medication (to treat HIV) for the first time, there are now a variety of different medicines which may be taken together as a combination in order to form an effective…
- Trial name
- NCT01736761
- Testing
- Darunavir, Ritonavir and Rilpivirine
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- St Stephens Aids Trust
HIV Infections
Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
This study will test the safety of and immune response to an oral HIV vaccine in healthy volunteers. The vaccine in this study uses a weakened bacterium called Salmonella typhi to deliver an HIV gene into the body through the…
- Trial name
- NCT00062530
- Testing
- SCBaL/M9
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV I Infection
Low Dose Nivolumab in Adults Living With HIV on Antiretroviral Therapy
The purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir.
- Trial name
- NIVO-LD (NCT05187429)
- Testing
- Nivolumab 10 MG/ML [Opdivo], Saline
- Where
- 2 sites in Australia, Singapore
- Volunteers
- 42 people
- Sponsor
- University of Melbourne
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.